Company news

Moleculin Biotech, Inc. news in 2021

Moleculin Biotech, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

December 26, 2021

Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme

November 30, 2021

Moleculin Reports Third Quarter 2021 Financial Results and Provides Programs Update

November 10, 2021

Moleculin Receives Authorization from the Medicines and Healthcare Products Regulatory Agency (MHRA) to Commence Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19

October 18, 2021

Moleculin Announces Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases

October 17, 2021

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update

August 11, 2021

Moleculin Receives Approval to Extend Dose Escalation in Phase 1/2 European Clinical Trial Evaluating Annamycin for the Treatment of Acute Myeloid Leukemia

July 12, 2021

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

June 20, 2021

Moleculin Announces Inclusion in the Russell 2000® Index

June 14, 2021

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

May 24, 2021

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

May 11, 2021

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

April 13, 2021

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

April 5, 2021

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

March 29, 2021

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

March 23, 2021

Moleculin Announces Full Exercise of Over-Allotment Option

February 9, 2021

Moleculin Announces Grant Awarded to Polish Research Institute for Independent Clinical Trial of Annamycin in Sarcoma Lung Metastases

February 7, 2021

Moleculin Announces Pricing Of $67.8 Million Underwritten Public Offering

February 2, 2021

Moleculin Announces Proposed Underwritten Public Offering

February 1, 2021

Moleculin Signs Agreement with Catalyst Clinical Research to Begin Sarcoma Trial

January 31, 2021

Decks in 2021